Articles with public access mandates - Daniel J. VisLearn more
Not available anywhere: 2
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
N van Dijk, A Gil-Jimenez, K Silina, K Hendricksen, LA Smit, JM de Feijter, ...
Nature medicine 26 (12), 1839-1844, 2020
Mandates: Swiss National Science Foundation, Worldwide Cancer Research, UK
Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer
A Gil-Jimenez, J van Dorp, A Contreras-Sanz, K van der Vos, DJ Vis, ...
European urology 83 (4), 313-317, 2023
Mandates: Netherlands Organisation for Scientific Research
Available somewhere: 23
A landscape of pharmacogenomic interactions in cancer
F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ...
Cell 166 (3), 740-754, 2016
Mandates: US National Institutes of Health, Netherlands Organisation for Scientific …
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
SN Ooft, F Weeber, KK Dijkstra, CM McLean, S Kaing, E van Werkhoven, ...
Science translational medicine 11 (513), eaay2574, 2019
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society
Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality
E Gogola, AA Duarte, JR de Ruiter, WW Wiegant, JA Schmid, R de Bruijn, ...
Cancer cell 33 (6), 1078-1093. e12, 2018
Mandates: Swiss National Science Foundation, Danish National Research Foundation …
Subunit composition of VRAC channels determines substrate specificity and cellular resistance to P t‐based anti‐cancer drugs
R Planells‐Cases, D Lutter, C Guyader, NM Gerhards, F Ullrich, DA Elger, ...
The EMBO journal 34 (24), 2993-3008, 2015
Mandates: Swiss National Science Foundation, German Research Foundation, Netherlands …
Effective drug combinations in breast, colon and pancreatic cancer cells
P Jaaks, EA Coker, DJ Vis, O Edwards, EF Carpenter, SM Leto, L Dwane, ...
Nature 603 (7899), 166-173, 2022
Mandates: Cancer Research UK, Wellcome Trust, European Commission, Government of Italy …
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer
M Michaut, SF Chin, I Majewski, TM Severson, T Bismeijer, L De Koning, ...
Scientific reports 6 (1), 1-13, 2016
Mandates: National Health and Medical Research Council, Australia, Cancer Research UK …
Intra‐and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts
K Kemper, O Krijgsman, P Cornelissen‐Steijger, A Shahrabi, F Weeber, ...
EMBO molecular medicine 7 (9), 1104-1118, 2015
Mandates: Cancer Research UK, Wellcome Trust, European Commission, Dutch Cancer Society
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models
Z Xue, DJ Vis, A Bruna, T Sustic, S van Wageningen, AS Batra, ...
Cell research 28 (7), 719-729, 2018
Mandates: Cancer Research UK, Dutch Cancer Society
Facilitating a culture of responsible and effective sharing of cancer genome data
LL Siu, M Lawler, D Haussler, BM Knoppers, J Lewin, DJ Vis, RG Liao, ...
Nature medicine 22 (5), 464-471, 2016
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, Cancer …
TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types
N Aben, DJ Vis, M Michaut, LF Wessels
Bioinformatics 32 (17), i413-i420, 2016
Mandates: European Commission
Identification of a druggable pathway controlling glioblastoma invasiveness
N Pencheva, MC de Gooijer, DJ Vis, LFA Wessels, T Würdinger, ...
Cell reports 20 (1), 48-60, 2017
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society …
P athogenic and targetable genetic alterations in 70 urachal adenocarcinomas
H Reis, KE van der Vos, C Niedworok, T Herold, O Módos, A Szendrői, ...
International Journal of Cancer 143 (7), 1764-1773, 2018
Mandates: Hungarian Academy of Sciences, National Office for Research, Development and …
Evaluation of the HER/PI3K/AKT family signaling network as a predictive biomarker of pathologic complete response for patients with breast cancer treated with neratinib in the …
JD Wulfkuhle, C Yau, DM Wolf, DJ Vis, RI Gallagher, L Brown-Swigart, ...
JCO precision oncology 2, 1-20, 2018
Mandates: US National Institutes of Health
Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning
SMC Mourragui, M Loog, DJ Vis, K Moore, AG Manjon, MA van de Wiel, ...
Proceedings of the National Academy of Sciences 118 (49), e2106682118, 2021
Mandates: Netherlands Organisation for Health Research and Development
TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
SAL Palit, D Vis, S Stelloo, C Lieftink, S Prekovic, E Bekers, I Hofland, ...
Elife 8, e47430, 2019
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape
DJ Vis, J Lewin, RG Liao, M Mao, F Andre, RL Ward, F Calvo, BT Teh, ...
Annals of Oncology 28 (5), 1145-1151, 2017
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, UK …
The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer
N Dijk, A Gil-Jimenez, K Silina, ML Montfoort, S Einerhand, L Jonkman, ...
Frontiers in Immunology 12, 793964, 2021
Mandates: Swiss National Science Foundation, Worldwide Cancer Research, UK
Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
Y Kim, T Bismeijer, W Zwart, LFA Wessels, DJ Vis
Nature communications 10 (1), 5034, 2019
Mandates: Netherlands Organisation for Scientific Research, European Commission, Dutch …
Publication and funding information is determined automatically by a computer program